Recurrence-free survival after total thyroidectomy and lobectomy in patients with papillary thyroid microcarcinoma.


Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 17 04 2020
accepted: 22 06 2020
pubmed: 12 7 2020
medline: 6 11 2021
entrez: 12 7 2020
Statut: ppublish

Résumé

The incidence of papillary thyroid microcarcinoma is increasing. We evaluated the recurrence-free survival following total thyroidectomy and lobectomy to identify the optimal surgical choice. A meta-analysis was performed using the National Library of Medicine and the National Institutes of Health PubMed database to identify eligible studies. Summary 5- and 10-year RFS estimates after TT versus LT were calculated using random effects models. The literature search yielded 1117 studies (1990-2019). Nine studies met the inclusion criteria comprising 10,186 total thyroidectomy and 11,408 lobectomy patients. The 5-year recurrence-free survival was 98% [95% confidence interval (CI) 97-99%] after total thyroidectomy and 97% (95% CI 96-99%) after lobectomy, based on eight studies (9421 total thyroidectomy and 11,283 lobectomy patients); the 10-year recurrence-free survival was 95% (95% CI 92-98%) after total thyroidectomy and 92% (95% CI 86-96%) after lobectomy, based on eight studies (total thyroidectomy = 10,100, lobectomy = 11,389 patients). The present meta-analysis demonstrates excellent, long-term recurrence-free survival following both total thyroidectomy and lobectomy surgery in patients with papillary thyroid microcarcinoma. The analysis also suggests that patients undergoing total thyroidectomy trended toward a slightly better long-term 10-year recurrence-free survival in comparison to patients undergoing lobectomy, a finding of potential, clinical significance in the management decision-making process.

Identifiants

pubmed: 32651895
doi: 10.1007/s40618-020-01342-1
pii: 10.1007/s40618-020-01342-1
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-734

Références

Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140(4):317–322. https://doi.org/10.1001/jamaoto.2014.1
doi: 10.1001/jamaoto.2014.1 pubmed: 24557566
Kitahara CM, Sosa JA (2016) The changing incidence of thyroid cancer. Nat Rev Endocrinol 12(11):646–653. https://doi.org/10.1038/nrendo.2016.110
doi: 10.1038/nrendo.2016.110 pubmed: 27418023
Lim H, Devesa SS, Sosa JA et al (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317(13):1338–1348. https://doi.org/10.1001/jama.2017.2719
doi: 10.1001/jama.2017.2719 pubmed: 28362912
Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18):2164–2167. https://doi.org/10.1001/jama.295.18.2164
doi: 10.1001/jama.295.18.2164 pubmed: 16684987
Welch HG, Doherty GM (2018) Saving thyroids—overtreatment of small papillary cancers. N Engl J Med 379(4):310–312. https://doi.org/10.1056/NEJMp1804426
doi: 10.1056/NEJMp1804426 pubmed: 30044933
Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020 pubmed: 4739132 pmcid: 4739132
Loyo M, Tufano RP, Gourin CG (2013) National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 123(8):2056–2063. https://doi.org/10.1002/lary.23923
doi: 10.1002/lary.23923 pubmed: 23737403
Hauch A, Al-Qurayshi Z, Randolph G et al (2014) Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 21(12):3844–3852. https://doi.org/10.1245/s10434-014-3846-8
doi: 10.1245/s10434-014-3846-8 pubmed: 24943236
Macedo FI, Mittal VK (2015) Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: a meta-analysis. Surg Oncol 24(2):117–122. https://doi.org/10.1016/j.suronc.2015.04.005
doi: 10.1016/j.suronc.2015.04.005 pubmed: 25956302
Zheng W, Li J, Lv P, Chen Z et al (2018) Treatment efficacy between total thyroidectomy and lobectomy for patients with papillary thyroid microcarcinoma: a systemic review and meta-analysis. Eur J Surg Oncol 44(11):1679–1684. https://doi.org/10.1016/j.ejso.2018.08.004
doi: 10.1016/j.ejso.2018.08.004 pubmed: 30158063
Wells GA, Shea B, O’Connell D et al (2020) The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. University of Ottawa. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 13 Feb 2020
Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z
doi: 10.1007/s10654-010-9491-z
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186
doi: 10.1002/sim.1186 pubmed: 12111919
Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335(7626):914–916. https://doi.org/10.1136/bmj.39343.408449.80
doi: 10.1136/bmj.39343.408449.80 pubmed: 17974687 pmcid: 2048840
Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002. https://doi.org/10.1136/bmj.d4002
doi: 10.1136/bmj.d4002 pubmed: 21784880
Hay ID, Hutchinson ME, Gonzalez-Losada T et al (2008) Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144(6):980–987. https://doi.org/10.1016/j.surg.2008.08.035 (discussion 7–8)
doi: 10.1016/j.surg.2008.08.035 pubmed: 19041007
Gershinsky M, Barnett-Griness O, Stein N et al (2012) Total versus hemithyroidectomy for microscopic papillary thyroid cancer. J Endocrinol Invest 35(5):464–468. https://doi.org/10.3275/7963
doi: 10.3275/7963 pubmed: 21952495
Lee J, Park JH, Lee CR et al (2013) Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid 23(11):1408–1415. https://doi.org/10.1089/thy.2012.0463
doi: 10.1089/thy.2012.0463 pubmed: 23509895
Donatini G, Castagnet M, Desurmont T et al (2016) Partial thyroidectomy for papillary thyroid microcarcinoma: is completion total thyroidectomy indicated? World J Surg 40(3):510–515. https://doi.org/10.1007/s00268-015-3327-7
doi: 10.1007/s00268-015-3327-7 pubmed: 26546190
Dobrinja C, Pastoricchio M, Troian M et al (2017) Partial thyroidectomy for papillary thyroid microcarcinoma: is completion total thyroidectomy indicated? Int J Surg 41(Suppl 1):S34–S39. https://doi.org/10.1016/j.ijsu.2017.02.012
doi: 10.1016/j.ijsu.2017.02.012 pubmed: 28506411
Kim SK, Park I, Woo JW et al (2017) Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8,676 patients at a single institution. Surgery 161(2):485–492. https://doi.org/10.1016/j.surg.2016.07.037
doi: 10.1016/j.surg.2016.07.037 pubmed: 27593085
Kwon H, Jeon MJ, Kim WG et al (2017) A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. Eur J Endocrinol 176(4):371–378. https://doi.org/10.1530/EJE-16-0845
doi: 10.1530/EJE-16-0845 pubmed: 28089996
Choi JB, Lee WK, Lee SG et al (2018) Long-term oncologic outcomes of papillary thyroid microcarcinoma according to the presence of clinically apparent lymph node metastasis: a large retrospective analysis of 5,348 patients. Cancer Manag Res 10:2883–2891. https://doi.org/10.2147/CMAR.S173853
doi: 10.2147/CMAR.S173853 pubmed: 30214283 pmcid: 6118257
Xu Y, Xu L, Wang J (2018) Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. J Surg Res 221:128–134. https://doi.org/10.1016/j.jss.2017.08.007
doi: 10.1016/j.jss.2017.08.007 pubmed: 29229118
Tuttle RM, Fagin JA, Minkowitz G et al (2017) Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 143(10):1015–1020. https://doi.org/10.1001/jamaoto.2017.1442
doi: 10.1001/jamaoto.2017.1442 pubmed: 28859191 pmcid: 5710258
Sakai T, Sugitani I, Ebina A et al (2019) Active surveillance for T1bN0M0 papillary thyroid carcinoma. Thyroid 29(1):59–63. https://doi.org/10.1089/thy.2018.0462
doi: 10.1089/thy.2018.0462 pubmed: 30560718
Ito Y, Miyauchi A, Oda H (2018) Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol 44:307–315. https://doi.org/10.1016/j.ejso.2017.03.004
doi: 10.1016/j.ejso.2017.03.004 pubmed: 28343733
Leboulleux S, Tuttle RM, Pacini F et al (2016) Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol 4(11):933–942. https://doi.org/10.1016/S2213-8587(16)30180-2
doi: 10.1016/S2213-8587(16)30180-2 pubmed: 27550849
Molinaro E, Campopiano MC, Pieruzzi L et al (2020) Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center. J Clin Endocrinol Metab 105(3):dgz113. https://doi.org/10.1210/clinem/dgz113
doi: 10.1210/clinem/dgz113 pubmed: 31652318
Tuttle RM, Haugen B, Perrier ND (2017) Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 27(6):751–756. https://doi.org/10.1089/thy.2017.0102
doi: 10.1089/thy.2017.0102 pubmed: 28463585 pmcid: 5467103
Mehanna H, Al-Maqbili T, Carter B et al (2014) Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21,329 person-years of follow-up. J Clin Endocrinol Metab 99(8):2834–2843. https://doi.org/10.1210/jc.2013-2118
doi: 10.1210/jc.2013-2118 pubmed: 24828487
Niemeier LA, Kuffner Akatsu H, Song C et al (2012) A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 118(8):2069–2077. https://doi.org/10.1002/cncr.26425
doi: 10.1002/cncr.26425 pubmed: 21882177
Hu G, Zhu W, Yang W et al (2016) The effectiveness of radioactive iodine remnant ablation for papillary thyroid microcarcinoma: a systematic review and meta-analysis. World J Surg 40(1):100–109. https://doi.org/10.1007/s00268-015-3346-4
doi: 10.1007/s00268-015-3346-4 pubmed: 26578322
Kwon H, Jeon MJ, Kim WG et al (2017) Lack of efficacy of radioiodine remnant ablation for papillary thyroid microcarcinoma: verification using inverse probability of treatment weighting. Ann Surg Oncol 24(9):2596–2602. https://doi.org/10.1245/s10434-017-5910-7
doi: 10.1245/s10434-017-5910-7 pubmed: 28600731

Auteurs

M van Gerwen (M)

Department of Otolaryngology and Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, P. O. Box 1133, New York, NY, 10029, USA.

M Alsen (M)

Department of Otolaryngology and Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

E Lee (E)

Department of Otolaryngology and Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

C Sinclair (C)

Department of Otolaryngology and Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

E Genden (E)

Department of Otolaryngology and Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

E Taioli (E)

Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, P. O. Box 1133, New York, NY, 10029, USA. emanuela.taioli@mountsinai.org.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. emanuela.taioli@mountsinai.org.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. emanuela.taioli@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH